2025-11-24 - Analysis Report
Here's a comprehensive analysis of TransMedics Group Inc. (TMDX) based on the provided data:

**1. Return Rate Comparison:**

*   **Company Overview:** Transmedics Group Inc. is a medical technology company focused on developing and commercializing innovative organ care system (OCS) technology for end-stage organ failure patients.
*   **TMDX Cumulative Return:** 225.14%
*   **VOO (S&P 500) Cumulative Return:** 70.06%
*   **Divergence:** 155.1 (Relative Divergence: 71.4)

    *   **Analysis:** TMDX has significantly outperformed the S&P 500 over the given period. The divergence of 155.1 indicates a substantial performance gap. A relative divergence of 71.4 suggests the current performance difference is positioned above the historical average divergence between the two assets, but it is not as high as the maximum, indicating the performance may have potential to improve.

**Alpha, Beta Analysis:**

| Year      | CAGR     | MDD     | Alpha    | Beta    | Cap(B) |
| --------- | -------- | -------- | -------- | ------- | ------ |
| 2019-2021 | -18.0%  | 83.5%   | -61.0%   | -0.0    | 0.7    |
| 2020-2022 | 94.0%   | 83.5%   | 95.0%    | 0.0     | 2.1    |
| 2021-2023 | 65.0%   | 80.5%   | 64.0%    | 0.1     | 2.7    |
| 2022-2024 | 130.0%  | 85.5%   | 109.0%   | 0.1     | 2.1    |
| 2023-2025 | 146.0%  | 85.5%   | 87.0%    | 0.3     | 4.5    |

*   **CAGR:** Compound Annual Growth Rate shows strong growth in recent periods (2020-2025).
*   **MDD:** Maximum Drawdown remains high, indicating significant risk or volatility.
*   **Alpha:** Positive Alpha values indicate the stock consistently outperforms its benchmark.
*   **Beta:** Low Beta values (close to 0) suggest the stock's price is relatively independent of overall market movements (S&P 500).
*   **Cap(B):** Market capitalization is growing rapidly.

**2. Recent Stock Price Fluctuations:**

*   **Current Close:** 130.93
*   **Last Market Price:** 130.93, Previous Close: 123.82, Change: 5.74
*   **5-day SMA:** 123.74
*   **20-day SMA:** 125.12
*   **60-day SMA:** 118.34

    *   **Analysis:** The current price is above all three SMAs, suggesting an upward trend. The positive change in the last market also points to recent positive momentum. The 5-day SMA is lower than the 20-day SMA, which in turn is lower than the 60-day SMA. This means that the stock price has been rising faster in the short term than in the long term. The significant price change indicates recent volatility.

**3. Indicators:**

*   **MRI (Market Risk Indicator):** 0.8 (Medium Investment Recommended)
*   **RSI:** 55.12 (Neutral)
*   **PPO:** 0.32 (Positive Momentum)
*   **Hybrid Signal:** Buy 100% with a monthly investment of 1.2% of the total investment.
*   **Recent Divergence Change:** 13.5 (+), indicating short-term upward movement.
*   **Expected Return:** 38.9% (Long-term outlook)

    *   **Analysis:** The MRI suggests a medium investment risk. RSI is at a neutral level. PPO indicates positive momentum. The hybrid signal recommends a full buy position. The recent divergence change supports the upward trend. The expected return is promising.

**4. Recent News & Significant Events:**

*   **Positive Headlines:**
    *   "TMDX stock is up 13% today"
    *   "TransMedics (TMDX) is a Top-Ranked Growth Stock"
*   **Mixed Headlines:**
    *   "TMDX Stock Falls Despite Q3 Earnings Beat Estimates, Revenues Up Y/Y" (Shows mixed market reaction)
    *    "Is TMDX stock vulnerable to regulatory risks"
*   **Informative Headlines:**
    *   "TransMedics (Nasdaq: TMDX) to Host Fireside Chat" (Investor Relations activity)
    *   "TransMedics Reports Inducement Grants" (Corporate action)

    *   **Analysis:** Recent news presents a mixed picture. The positive headlines related to stock performance and growth stock status support an optimistic outlook. However, the headline about the stock falling despite earnings beats and potential regulatory risks raises concerns about market perception and potential future challenges.

**4-2. Analyst Opinions:**

*   **Consensus:** Buy (~1.67)
*   **Target Price:** 141.91 (Avg), 170.00 (High), 114.00 (Low)

    *   **Analysis:** Analyst consensus is strongly in favor of buying TMDX. The average target price of $141.91 suggests potential upside from the current price. However, a low target of $114.00 shows mixed expectations.

**5. Comprehensive Analysis:**

TMDX demonstrates strong growth potential, as evidenced by its high cumulative return, positive Alpha, and strong recent performance. Analyst ratings suggest continued confidence in the stock. The stock is currently trading at 130.93 with an analyst consensus target price of 141.91. This implies an upside of about 8.4%.

However, there are also risks to consider: high MDD indicates price volatility, and news suggests potential vulnerability to regulatory issues. The recent price surge (indicated by the high price change and short-term moving averages) could be followed by a correction. Investors should also be aware that while the recent divergence change is positive, the high relative divergence value suggests it may be trading at the high end of its historical range.

**In conclusion:**

TMDX appears to be a growth stock with significant potential. The technical indicators support this optimism with recent price action. However, investors should be aware of the inherent volatility and potential risks, and should balance any investment with appropriate risk management strategies. Also note that market risk indicator suggesting a medium investment indicates that the investor should be aware of market volatility, and that recent news mentions regulatory risk.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.